Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain

Sixty-nine Kenyan Plasmodium falciparum field isolates were tested in vitro against pyrimethamine (PM), chlorcycloguanil (CCG), sulfadoxine (SD), and dapsone (DDS), and their dihydrofolate reductase (DHFR) genotypes were determined. The in vitro data show that CCG is more potent than PM and that DDS...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Antimicrobial agents and chemotherapy Ročník 42; číslo 1; s. 164
Hlavní autori: Nzila-Mounda, A, Mberu, E K, Sibley, C H, Plowe, C V, Winstanley, P A, Watkins, W M
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.01.1998
Predmet:
Animals
Antimalarials - pharmacology
Humans
Kenya
Malaria, Falciparum - drug therapy
Plasmodium falciparum - drug effects
Plasmodium falciparum - enzymology
Point Mutation
Proguanil - analogs & derivatives
Proguanil - pharmacology
Protozoan Proteins - drug effects
Protozoan Proteins - genetics
Pyrimethamine - pharmacology
Sensitivity and Specificity
Tetrahydrofolate Dehydrogenase - drug effects
Tetrahydrofolate Dehydrogenase - genetics
Triazines
Kenya
ISSN:0066-4804
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Sixty-nine Kenyan Plasmodium falciparum field isolates were tested in vitro against pyrimethamine (PM), chlorcycloguanil (CCG), sulfadoxine (SD), and dapsone (DDS), and their dihydrofolate reductase (DHFR) genotypes were determined. The in vitro data show that CCG is more potent than PM and that DDS is more potent than SD. DHFR genotype is correlated with PM and CCG drug response. Isolates can be classified into three distinct groups based on their 50% inhibitory concentrations (IC50s) for PM and CCG (P < 0.01) and their DHFR genotypes. The first group consists of wild-type isolates with mean PM and CCG IC50s of 3.71 +/- 6.94 and 0.24 +/- 0.21 nM, respectively. The second group includes parasites which all have mutations at codon 108 alone or also at codons 51 or 59 and represents one homogeneous group for which 25- and 6-fold increases in PM and CCG IC50s, respectively, are observed. Parasites with mutations at codons 108, 51, and 59 (triple mutants) form a third distinct group for which nine- and eightfold increases in IC50s, respectively, of PM and CCG compared to the second group are observed. Surprisingly, there is a significant decrease (P < 0.01) of SD and DDS susceptibility in these triple mutants. Our data show that more than 92% of Kenyan field isolates have undergone at least one point mutation associated with a decrease in PM activity. These findings are of great concern because they may indicate imminent PM-SD failure, and there is no affordable antimalarial drug to replace PM-SD (Fansidar).
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0066-4804
DOI:10.1128/aac.42.1.164